ClinicalTrialsFinder
RecruitingPhase 1NCT07318675

A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW211026 Ointment After Single or Multiple Doses in Subjects With Actinic Keratosis

Sponsor

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Enrollment

40 participants

Start Date

Dec 25, 2025

Study Type

INTERVENTIONAL

Conditions

Actinic Keratosis (AK)

Summary

This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HW211026 and a drug called Placebo for people with actinic keratosis (ak). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHW211026

Dose 1 and Dose 2

DRUGPlacebo

Dose 1 and Dose 2

Locations(1)

Shanghai Skin Disease Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07318675

Related Trials

An Open-Label, Two-Cohort, Pharmacokinetic Study in a Maximal Use Setting for Patients With Actinic Keratosis on the Upper Extremities or the Face

NCT077295791 location

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

NCT076579882 locations

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT072863182 locations

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

NCT073406974 locations

Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses

NCT073350031 location